Zacks Investment Research lowered shares of Glaukos Corporation (NYSE:GKOS) from a strong-buy rating to a hold rating in a research note published on Wednesday.
According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “
GKOS has been the topic of a number of other research reports. Stephens upgraded Glaukos Corporation from an equal weight rating to an overweight rating in a report on Monday, May 8th. BMO Capital Markets restated a buy rating and issued a $54.00 price objective on shares of Glaukos Corporation in a report on Tuesday, April 11th. BidaskClub upgraded Glaukos Corporation from a hold rating to a buy rating in a report on Saturday, June 24th. TheStreet downgraded Glaukos Corporation from a c rating to a d+ rating in a report on Wednesday, May 3rd. Finally, Cantor Fitzgerald restated an overweight rating and issued a $54.00 price objective on shares of Glaukos Corporation in a report on Thursday, May 4th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $48.50.
Shares of Glaukos Corporation (GKOS) opened at 40.12 on Wednesday. Glaukos Corporation has a 1-year low of $28.26 and a 1-year high of $52.49. The firm’s 50-day moving average is $40.47 and its 200 day moving average is $42.42. The stock has a market capitalization of $1.38 billion, a P/E ratio of 364.73 and a beta of 1.33.
TRADEMARK VIOLATION WARNING: “Glaukos Corporation (NYSE:GKOS) Rating Lowered to Hold at Zacks Investment Research” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://transcriptdaily.com/2017/07/18/glaukos-corporation-nysegkos-rating-lowered-to-hold-at-zacks-investment-research.html.
Institutional investors have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System increased its position in shares of Glaukos Corporation by 1.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 7,699 shares of the medical instruments supplier’s stock valued at $264,000 after buying an additional 140 shares during the period. State Street Corp increased its position in shares of Glaukos Corporation by 6.9% in the fourth quarter. State Street Corp now owns 281,407 shares of the medical instruments supplier’s stock valued at $9,653,000 after buying an additional 18,183 shares during the period. AQR Capital Management LLC bought a new position in shares of Glaukos Corporation during the fourth quarter valued at approximately $513,000. Teachers Advisors LLC increased its position in shares of Glaukos Corporation by 5.7% in the fourth quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock valued at $953,000 after buying an additional 1,506 shares during the period. Finally, Highbridge Capital Management LLC bought a new position in shares of Glaukos Corporation during the fourth quarter valued at approximately $416,000. Institutional investors own 88.92% of the company’s stock.
About Glaukos Corporation
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.